Banner US IN.PACT Admiral Drug Coated Balloon

Durable. Consistent. Safe.

IN.PACT Admiral DCB demonstrates sustained durability of treatment effect through two years.

Primary Patency1 Results through 3 Years

3-year Primary Patency Outcomes from IN.PACT SFA Trial by Kaplan-Meier Analysis

KM Graph

Freedom from CD-TLR through 3 Years

Freedom from CD-TLR through 3 Years thumbnail

IN.PACT SFA Trial
Effectiveness Outcomes through 3 Years  

Effectiveness Outcomes through 3 Years thumbnail

IN.PACT SFA Trial
Safety Outcomes through 3 Years

Safety Outcomes through 3 Years thumbnail

Superior 3-year patency and low intervention rates with the IN.PACT™ Admiral™ Drug-Coated Balloon

  • Durable:  First independently adjudicated, randomized pivotal IDE trial to show durable treatment effect with a DCB through three years
  • Safety: Results demononstrate long-term safety of IN.PACT™ Admiral™ DCB
  • Paradigm Shift:  Data supports IN.PACT™ Admiral™ DCB as a first-line treatment for symptomatic femoropopliteal disease

IN.PACT SFA and IN.PACT GLOBAL support IN.PACT Admiral as a primary therapy in the treatment of SFA disease

  • The IN.PACT SFA Trial demonstrates superior safety and effectiveness of IN.PACT Admiral as compared to standard PTA.  Patient and Lesion charachteristics are comparable to other SFA pivotal trials.
  • The IN.PACT Global Study confirms safety and effectiveness of IN.PACT Admiral in a complex, real-world patient population and reinforces the market-leading outcomes from IN.PACT SFA.

IN.PACT Global: Study Design

IN.PACT Global: Study Design thumbnail

IN.PACT Global: Study Architecture

IN.PACT Global: Study Architecture thumbnail

IN.PACT Global Clinical Cohort: Primary Endpoint: Freedom from CD-TLR through 1 Year

FFreedom from CD-TLR through 1 Year thumbnail

12 Month Effectiveness Outcomes thumbnail

IN.PACT Global Clinical Cohort: 1-Year Safety Outcomes

IN.PACT Global Clinical Cohort 1-Year Safety Outcomes thumbnail

IN.PACT Admiral DCB Studies

Comparison of 12-month Outcomes

IN.PACT Admiral 12-month Outcomes thumbnail

UC201301645f EN